Evidence map›Paper›PMID 42446848›Full record

ReviewDiscover nano2026

Nanomaterial toxicity and risk assessment integrating functionalization strategies advanced in vitro models and regulatory perspectives.

Jitendra Patel, Harekrishna Roy, Deepak S Khobragade, Nihar Ranjan Das, Rukmani Patel, Poonam Lal, Balaji Maddina, Raghvendra Bohara

Abstract readReview
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jitendra Patel *Department of Pharmacognosy, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Sawangi (Meghe), Wardha, 442001, MS, India.
Harekrishna Roy *Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, 522503, Andhra Pradesh, India. hareroy@gmail.com.
Deepak S KhobragadeDepartment of Pharmacognosy, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Sawangi (Meghe), Wardha, 442001, MS, India.
Nihar Ranjan DasSchool of Pharmacy and Life Sciences, Centurion University of Technology Management, Bhubaneswar, Odisha, India.
Rukmani PatelDepartment of Chemistry, KMT Govt Girls College Raigarh, Chattisgarh, CG, India.
Poonam LalDepartment of Pharmacognosy, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Sawangi (Meghe), Wardha, 442001, MS, India.
Balaji MaddinaScientific Writing Services, Freyr Global Regulatory Solutions and Services, Phoenix SEZ, Hyderabad, India, Hyderabad, India.
Raghvendra BoharaDatta Meghe Institute of Higher Education, (Deemed to be University, Sawangi (Meghe), Wardha, 442001, MS, India. raghvendrabohara@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials have gained huge importance in various fields, such as healthcare, electronics, and environmental management, due to their unique characteristics. However, the potent toxicity is a big concern regarding their utility. Toxicological assessment becomes an important step to ensure their safe applications. The significant hazards of nanomaterials have risen from their shape, size, charge, and makeup, which leads to genetic damage, cellular uptake, and internalization with oxidative stress (OS) and harm to specific organs. This review focuses on toxicity profiles and their possible interactions with cellular organelles leading to apoptosis (Apop) and long-term bioaccumulation.Size, surface area, and dissolving capability may affect the toxicity of nanomaterials. Different measures such as encapsulation methods, increasing surface area, and enhancing biodegradability are being considered to reduce toxicity from innovative nanomaterials. Knowledge gaps encompass uneven toxicity evaluations, inadequate chronic exposure data, and insufficient attention to individualized reactions. The integration of standardized models, computational predictions, mechanistic investigations, and regulatory compliance is crucial for the safer design of nanomaterials. The review highlights toxicological issues caused by nanomaterials such as nanoformulation, quantum dots, and nanoparticles. It also directs future strategies in nanotoxicology, highlighting increasing assessment models, strategies, and collaborative research efforts. Bringing together regulatory and research efforts in the context of nanomaterials is important for ensuring the safe application of nanomaterials across pharmacy and other industries. This review offers a comprehensive viewpoint connecting physicochemical factors, sophisticated in vitro models, and developing regulatory frameworks, emphasizing emerging trends including microphysiological systems and animal-free risk assessment methodologies.

Indexed as

NanomaterialsNanomedicineRegulatory frameworksRisk assessmentSurface functionalizationToxicology

Identifiers

PMID42446848
PMCPMC13369107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.